Novaquest Capital Management, L.L.C is an investment fund managing more than $54.3 million ran by John Jr.. There are currently 2 companies in Mr. Jr.’s portfolio. The largest investments include Myovant Sciences and Revance Therapeutics, together worth $54.3 million.
As of 6th November 2020, Novaquest Capital Management, L.L.C’s top holding is 3,474,645 shares of Myovant Sciences currently worth over $48.8 million and making up 90.0% of the portfolio value.
Relative to the number of outstanding shares of Myovant Sciences, Novaquest Capital Management, L.L.C owns more than approximately 0.1% of the company.
In addition, the fund holds 216,038 shares of Revance Therapeutics worth $5.43 million, whose value grew 37.6% in the past six months.
Currently, Novaquest Capital Management, L.L.C's portfolio is worth at least $54.3 million. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
The Novaquest Capital Management, L.L.C office and employees reside in Raleigh, North Carolina. According to the last 13-F report filed with the SEC, John Jr. serves as the Manager at Novaquest Capital Management, L.L.C.
John Jr. disclosed a decreased stake in Revance Therapeutics by 0.6%.
This leaves the value of the investment at $5.43 million and 216,038 shares.
The two most similar investment funds to Novaquest Capital Management, L.L.C are Youngs Advisory Group, Inc and Davis Capital Management. They manage $54.1 million and $54.1 million respectively.
Novaquest Capital Management, L.L.C’s portfolio is diversified across 1 sector.
Currently, their heaviest sector is Health Care — making up 100.0% of
the total portfolio value.
The fund focuses on investments in the United Kingdom as
50.0% of the portfolio companies
are based in the United Kingdom.
The majority of the companies in the fund’s portfolio are large-cap stocks.
Stocks with a size of more than $10 billion in market cap make up
approximately 0.1% of the total holdings value.
On the other hand, small-cap stocks make up only approximately 0.1% of the portfolio.
The average market cap of the portfolio companies is close to $1.47 billion.
These positions were updated on November 13th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Myovant Sciences Ltd. |
No change
3,474,645
|
$48,819,000 | 89.99% |
| Revance Therapeutics, Inc. |
63.93%
216,038
|
$5,431,000 | 10.01% |
| No transactions found | |||
| Showing first 500 out of 2 holdings | |||